- Home
- NUVL vs SM Comparison
NUVL vs SM Comparison
Compare NUVL & SM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUVL | SM |
|---|---|---|
| Founded | 2017 | 1908 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 7.5B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | NUVL | SM |
|---|---|---|
| Price | $123.50 | $26.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | ★ $134.75 | $34.36 |
| AVG Volume (30 Days) | ★ 4.2M | 3.7M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,154,000,000.00 |
| Revenue This Year | N/A | $129.01 |
| Revenue Next Year | $1,239.49 | $6.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.24 |
| 52 Week Low | $71.14 | $17.45 |
| 52 Week High | $123.69 | $35.88 |
Technical Indicators
Market Signals| Indicator | NUVL | SM |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 32.59 |
| Support Level | $97.99 | $24.88 |
| Resistance Level | $123.62 | $28.59 |
| Average True Range (ATR) | 0.58 | 1.27 |
| MACD | 0.66 | -0.55 |
| Stochastic Oscillator | 99.45 | 5.41 |
Price Performance
Historical ComparisonAbout NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. The Company operates in the oil and gas extraction industry, focused on exploration and production activities, onshore in the United States. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.